| Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE … LQM Chow, R Haddad, S Gupta, A Mahipal, R Mehra, M Tahara, R Berger, ... Journal of Clinical Oncology 34 (32), 3838-3845, 2016 | 875 | 2016 |
| Evolution of neoantigen landscape during immune checkpoint blockade in non–small cell lung cancer V Anagnostou, KN Smith, PM Forde, N Niknafs, R Bhattacharya, J White, ... Cancer discovery 7 (3), 264-276, 2017 | 871 | 2017 |
| Pembrolizumab for platinum-and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study J Bauml, TY Seiwert, DG Pfister, F Worden, SV Liu, J Gilbert, NF Saba, ... Journal of Clinical Oncology 35 (14), 1542-1549, 2017 | 677 | 2017 |
| Efficacy of Selpercatinib in RET-Altered Thyroid Cancers LJ Wirth, E Sherman, B Robinson, B Solomon, H Kang, J Lorch, F Worden, ... New England Journal of Medicine 383 (9), 825-835, 2020 | 674 | 2020 |
| Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas Y Wang, S Springer, CL Mulvey, N Silliman, J Schaefer, M Sausen, ... Science translational medicine 7 (293), 293ra104-293ra104, 2015 | 560 | 2015 |
| Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012 R Mehra, TY Seiwert, S Gupta, J Weiss, I Gluck, JP Eder, B Burtness, ... British journal of cancer 119 (2), 153-159, 2018 | 423 | 2018 |
| Emerging biomarkers in head and neck cancer in the era of genomics H Kang, A Kiess, C Chung Nature Reviews Clinical Oncology, 2014 | 323 | 2014 |
| Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open … V Subbiah, J Wolf, B Konda, H Kang, A Spira, J Weiss, M Takeda, Y Ohe, ... The Lancet Oncology 23 (10), 1261-1273, 2022 | 228 | 2022 |
| Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing CH Chung, VB Guthrie, DL Masica, C Tokheim, H Kang, J Richmon, ... Annals of oncology 26 (6), 1216-1223, 2015 | 198 | 2015 |
| Head and neck PET/CT: therapy response interpretation criteria (Hopkins criteria)—interreader reliability, accuracy, and survival outcomes C Marcus, A Ciarallo, AK Tahari, E Mena, W Koch, RL Wahl, AP Kiess, ... Journal of nuclear medicine 55 (9), 1411-1416, 2014 | 185 | 2014 |
| Differences in the prevalence of human papillomavirus (HPV) in head and neck squamous cell cancers by sex, race, anatomic tumor site, and HPV detection method G D’Souza, WH Westra, SJ Wang, A Van Zante, A Wentz, N Kluz, E Rettig, ... JAMA oncology 3 (2), 169-177, 2017 | 144 | 2017 |
| Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study R Kurzrock, DW Bowles, H Kang, F Meric-Bernstam, J Hainsworth, ... Annals of Oncology 31 (3), 412-421, 2020 | 107 | 2020 |
| Salivary Secretory Carcinoma With a Novel ETV6-MET Fusion: Expanding the Molecular Spectrum of a Recently Described Entity L Rooper, K Theodoros, Y Ning, J Bishop, S Gordon, H Kang American Journal of Surgical Pathology, 2018 | 106 | 2018 |
| Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas WJ Ho, M Yarchoan, A Hopkins, R Mehra, S Grossman, H Kang Journal for ImmunoTherapy of Cancer 6, 84, 2018 | 99 | 2018 |
| Whole-exome sequencing of salivary gland mucoepidermoid carcinoma H Kang, M Tan, JA Bishop, S Jones, M Sausen, PK Ha, N Agrawal Clinical Cancer Research 23 (1), 283-288, 2017 | 90 | 2017 |
| Salivary duct carcinoma: an aggressive salivary gland malignancy with opportunities for targeted therapy NC Schmitt, H Kang, A Sharma Oral oncology 74, 40-48, 2017 | 89 | 2017 |
| Personalized medicine in the oncology clinic: implementation and outcomes of the Johns Hopkins molecular tumor board WB Dalton, PM Forde, H Kang, RM Connolly, V Stearns, CD Gocke, ... JCO precision oncology 1, 1-19, 2017 | 88 | 2017 |
| High-resolution microbiome profiling uncovers Fusobacterium nucleatum, Lactobacillus gasseri/johnsonii, and Lactobacillus vaginalis associated to oral and oropharyngeal cancer … R Guerrero-Preston, JR White, F Godoy-Vitorino, A Rodríguez-Hilario, ... Oncotarget 8 (67), 110931, 2017 | 82 | 2017 |
| Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC) K Jung, H Kang, R Mehra Cancers of the head & neck 3, 1-13, 2018 | 75 | 2018 |
| SMAD4 loss is associated with cetuximab resistance and induction of MAPK/JNK activation in head and neck cancer cells H Ozawa, RS Ranaweera, E Izumchenko, E Makarev, A Zhavoronkov, ... Clinical Cancer Research 23 (17), 5162-5175, 2017 | 69 | 2017 |
Robert Haddad, M.D.Professor, Dana Farber Cancer Institute, Harvard Medical School, McGraw Chair Head and Neck OncologyDirección de correo verificada de dfci.harvard.edu
